Preclinical and clinical studies of MMP inhibitors in cancer

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 228-235

  Drummond, Alan H ^a   Beckett, Paul ^a   Brown, Peter D ^a   Bone, Elisabeth A ^a   Davidson, Alan H ^a   Galloway, W Alan ^a   Gearing, Andy J H ^a   Huxley, Phil ^a   Laber, David ^a   McCourt, Matthew ^a   Whittaker, Mark ^a   Wood, L Michael ^a   Wright, Annette ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GROWTH; CONFERENCE PAPER; DRUG EFFECT; HUMAN; NONHUMAN; TENDINITIS;

ANIMALIA;

EID: 0032864579     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07688.x     Document Type: Conference Paper

References (24)

1. 1. Brown, P.D. 1997. Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol. 14: 1-10.
2. 2. Wilhelm, S.M., A.Z. Eisen, M. Teter et al. 1986. Human fibroblast collagenase: glycosylation and tissue specific levels of enzyme synthesis. Proc. Natl. Acad. Sci. USA 83: 3756-3760
3. 3. Hasty, K.A., T.F. Pourmotabbed, G.I. Goldberg et al. 1990. Human neutrophil collagenase: a distinct gene product with homology to other matrix metalloproteinases. J. Biol. Chem. 265: 11421-11424.
4. 4. Freije, J.M., I. Biez-Itza, M. Balbin et al. 1994. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269: 16766-16773.
5. 5. Collier, I.E., S.M. Wilhelm, A.Z. Eisen et al. 1988. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J. Biol. Chem. 263: 6579-6587.
6. 6. Pei, D., G. Majmudar & S.J. Weiss. 1994. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 269: 25849-25855.
7. 7. Crimmin, M.J., W.A. Galloway & A.J.H. Gearing, inventors; British Biotech, assignee. 1993. U.S. patent 5,691,382. Date of application: November 12th.
8. 8. Gearing, A.J.H., P. Beckett, M. Christodoulou et al. 1994. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555-557.
9. 9. Ehlers, M.R.W. & J.F. Riordan. 1991. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry 30: 10065-10074.
10. 10. Arribas, J., L. Coodly, P. Vollmer et al. 1996. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 27: 11376-11382.
11. 11. Black, R.A., F.H. Durie, C. Otten-Evans et al. 1996. Relaxed specificity of matrix metalloproteinases and TIMP insensitivity of tumor necrosis factor α production suggest the major TNFα-converting enzyme is not an MMP. Biochem. Biophys. Res. Commun. 225: 400-405.
12. 12. Black, R.A., C.T. Rauch, C.J. Kozlosky et al. 1997. A metalloproteinase disintegrin that releases tumour necrosis factor α from cells. Nature 385: 729-732.
13. 13. Moss, M.L. S-L.C. Jin, M.E. Milla et al. 1997. Cloning of a disintegrin metalloproteinase that processes TNFα. Nature 385: 733-736.
14. 14. Stetler-Stevenson, W.G., S. Aznovoorian & L.A. Liotta. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell. Biol. 9: 541-573.
15. 15. Murray, G.I., M.E. Duncan, P. O'Neil et al. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 2: 461-462.
16. 16. Van Der Stappen, J.W.J., T. Hendricks & T. Wobbes. 1990. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumours. Int. J. Cancer 45: 1071-1078.
17. 17. Duncan, M.E., G.I. Murray, P. O'Neil, W.T. Melvin & J.E. Fothergill. 1996. Expression of matrix metalloproteinase in colorectal cancer. Biochem. Soc. Trans. 24: 3295.
18. 18. Beckett, P., A.H. Davidson, A.H. Drummond et al. 1996. Recent advances in matrix metalloproteinase inhibitor research. Drug. Dev. Today 1: 16-26
19. 19. Whittaker, M. & P.D. Brown. 1998. Recent advances in matrix metalloproteinase inhibitor research and development. Curr. Opin. Drug Disc. Dev. 1: 157-164.
20. 20. Ngo, J., A. Graul & J. Castaner. 1996. Batimastat. Drugs Future 21: 1215-1220.
21. 21. Drummond, A.H., P. Beckett, E.A. Bone et al. 1995. BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc. Am. Assoc. Cancer Res. 36: 100.
22. 22. Millar, A.W., P.D. Brown, J. Moore et al. 1998. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy volunteers. Br. Clin. Pharmacol. 45: 21-26.
23. 23. Nemunaitis, J., C. Poole, J. Primrose et al. 1998. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer term studies. Clin. Cancer Res. 4: 1101-1111.
24. 24. An, Z., X. Wang, N. Willmott et al. 1997. Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metastasis. 15: 184-195.